| 21 |
Design and synthesis of New dihydropyrimidine/sulphonamide hybrids as promising anti-inflammatory agents via dual mPGES-1/5-LOX inhibition |
2024 |
| 22 |
Design and synthesis of novel quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases |
2024 |
| 23 |
Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives |
2024 |
| 24 |
Design, synthesis, and antiproliferative activity of new 1, 2, 3-triazole/quinazoline-4-one hybrids as dual EGFR/BRAF V600E inhibitors |
2024 |
| 25 |
Design, synthesis, and antiproliferative activity of new indole/1,2,4-triazole/chalcone hybrids as EGFR and/or c-MET inhibitors |
2024 |
| 26 |
Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors |
2024 |
| 27 |
Design, synthesis, and biological evaluation of novel quinoline-based EGFR/HER-2 dual-target inhibitors as potential antitumor agents |
2024 |
| 28 |
Design, synthesis, biological evaluation and docking study of some new aryl and heteroaryl thiomannosides as FimH antagonists. |
2024 |
| 29 |
Discovery of new Schiff bases of the disalicylic acid scaffold as DNA gyrase and Topoisomerase IV inhibitors endowed with antibacterial properties |
2024 |
| 30 |
Hybrids of 4-aminosalicylic acid with dual anti-mycobacterial and anti-inflammatory activities: Synthesis, biological evaluation, in silico investigation and structure-activity relationships exploration |
2024 |
